As previously reported, Wedbush upgraded Cross Country Healthcare to Outperform from Perform with a price target of $15, up from $11, following a management meeting that increased the firm's conviction in "the timing and achievability" of the company's revenue stabilization expectations, profitability recovery and tech-enabled strategic pivot. Additionally, the recent pullback in shares creates a positively skewed risk/reward profile, Wedbush adds.
